Overview
Cathie Wood's genomics conviction portfolio — 35 names across sequencing, gene editing, liquid biopsy and AI-driven drug discovery, actively managed with ARK's signature concentration.
Top Holdings
| Ticker | Holding | Weight |
|---|---|---|
| TXG | 10x Genomics | 8.8% |
| TEM | Tempus AI | 8.3% |
| TWST | Twist Bioscience | 8.1% |
| CRSP | CRISPR Therapeutics | 5.4% |
| GH | Guardant Health | 5.1% |
| ILMN | Illumina | 5.0% |
| NTRA | Natera | 5.0% |
| ABSI | Absci Corp. | 4.9% |
| LLY | Eli Lilly | 4.2% |
| CDNA | CareDx | 3.9% |
Fund Details
Investment Thesis
The deepest-drawdown ARK fund became this year's comeback: +53% as AI collided with biology — Tempus, Absci and the sequencing complex re-rated on the thesis that drug discovery is becoming a computational problem. ARK's concentration cuts both ways, as the -54% of 2022 proved; buyers today are getting the same aggressive book three-quarters below its 2021 peak, with CRISPR-based medicine finally generating approvals and revenue rather than promises.
Who It's For
High-conviction growth investors who want the genomics-meets-AI thesis at full strength — a volatile satellite position for believers in computational biology's decade.
10-Year History
| Year | Close | % Chg |
|---|---|---|
| 2016 | $16.93 | -- |
| 2017 | $24.49 | +44.7% |
| 2018 | $23.98 | -2.1% |
| 2019 | $33.52 | +39.8% |
| 2020 | $93.26 | +178.2% |
| 2021 | $61.24 | -34.3% |
| 2022 | $28.23 | -53.9% |
| 2023 | $32.81 | +16.2% |
| 2024 | $23.55 | -28.2% |
| 2025 | $28.97 | +23.0% |
| Year | Yield |
|---|---|
| 2016 | 0.00% |
| 2017 | 0.00% |
| 2018 | 0.00% |
| 2019 | 0.00% |
| 2020 | 0.00% |
| 2021 | 0.00% |
| 2022 | 0.00% |
| 2023 | 0.00% |
| 2024 | 0.00% |
| 2025 | 0.00% |
| Year | AUM | % Chg |
|---|---|---|
| 2016 | $1.1B | -- |
| 2017 | $1.6B | +45.5% |
| 2018 | $1.6B | +0.0% |
| 2019 | $2.3B | +43.7% |
| 2020 | $6.4B | +178.3% |
| 2021 | $4.2B | -34.4% |
| 2022 | $1.9B | -54.8% |
| 2023 | $2.3B | +21.1% |
| 2024 | $1.6B | -30.4% |
| 2025 | $2B | +25.0% |
Price history from exchange data. Dividend yields from reported distributions; some earlier years are derived from total-return vs price-return data or are ETFHub estimates. AUM history is an ETFHub estimate modelled from current assets and annual returns (fund flows not reflected) and may differ from official fund records. Data as of October 2026.
Related US Sectors ETFs
Markets. Intelligence. Daily.
Full briefs on 500+ ETFs, curated daily ETF news, and a free weekly deep-dive newsletter — all on ETFHub.
Get the Free Weekly Brief Explore the ETF Portal Official Fund Page →